Merck's Drug Aced One Test and Bombed the Other. That Tells Us a Lot.

The problem? SSc-ILD isn't just an inflammatory disease. It's a tangled mess of inflammation, fibrosis (scarring), and blood vessel damage, all happening simultaneously. Trying to fix it by blocking one inflammatory signal is a bit like trying to stop a flood by plugging one hole in a dam that has twenty.

Merck's R&D chief reportedly said something revealing: "I don't know any anti-cytokine that has worked" in SSc-ILD. That's a remarkably candid admission. Bosentan and now tulisokibart have stumbled in this space, while tocilizumab showed some preservation of lung function but missed its primary skin endpoint. The consistent pattern suggests the biology of lung scarring is difficult to address with drugs that primarily dial down inflammation.

The one drug that has shown some traction is nintedanib, which works as a direct anti-fibrotic rather than an anti-inflammatory. That distinction matters: it hints that once fibrosis is underway in SSc-ILD, stopping the scarring machinery directly may matter more than quieting the immune system.

Why One Drug Can't Be Everything

Tulisokibart is a monoclonal antibody that targets TL1A, a protein that drives inflammatory signaling in immune cells. Think of TL1A as a megaphone that amplifies the immune system's alarm bells. Blocking it can cool down inflammation in diseases where the immune system is doing most of the damage (like HS). But in diseases where fibrosis has taken the wheel, silencing the megaphone doesn't stop the machinery that's already running.

This is a recurring theme in drug development. A mechanism that works brilliantly in one disease can flop in another, even when the two diseases share surface-level similarities. Inflammation is a common thread in both HS and SSc-ILD, but the underlying wiring is fundamentally different. Merck just learned that lesson in real time.

A Crowded Fight for HS

The good news for Merck is that its HS program survives. The bad news is that HS is turning into one of the most competitive battlegrounds in immunology.

AbbVie is running Phase 3 trials with both upadacitinib (an oral JAK1 inhibitor) and lutikizumab (an anti-IL-1 biologic). Novartis is pushing remibrutinib (a BTK inhibitor) alongside its established IL-17 franchise with secukinumab. UCB, Incyte, and MoonLake are all in the mix, too.

The variety of mechanisms in play tells you something important: nobody has cracked the code on HS yet. No single pathway has emerged as the clear winner, which means the eventual champions will likely be decided by a combination of efficacy, side effects, and dosing convenience rather than mechanism alone.

For Merck, the TL1A angle gives tulisokibart a differentiated story. But differentiation only matters if the data holds up in Phase 3.

The Bigger Picture for Merck

Zoom out, and tulisokibart is about much more than skin disease. It's a cornerstone of Merck's post-Keytruda survival plan.

Merck acquired tulisokibart through its $10.8 billion purchase of Prometheus, a deal that brought both the drug and a precision-medicine platform built on genetics and biomarkers. The thesis: TL1A blockade could work across multiple inflammatory diseases, giving Merck a scalable franchise similar to how Keytruda expanded across dozens of cancer types.

That thesis just got a reality check. The SSc-ILD failure narrows the drug's potential footprint. But the HS win, combined with encouraging Phase 3 results in ulcerative colitis reported earlier this year, keeps the core story intact. Tulisokibart still has a path to becoming a multi-indication asset; the map just got a little smaller.

Merck has been busy de-risking its future in other ways, too, scooping up Verona Pharma (respiratory), Cidara Therapeutics (infectious disease), and Terns Pharmaceuticals (oncology) in recent deals. The company clearly knows that relying on any single drug or mechanism is a dangerous game.

The Takeaway

Tulisokibart's split results aren't a failure story. They're a clarity story. Merck now knows exactly where this drug works and where it doesn't. In pharma, that kind of precision is actually valuable; it means the company can concentrate resources on indications where the biology is on its side instead of chasing long shots.

The HS opportunity is real, the competitive landscape is fierce, and the SSc-ILD graveyard just got a new headstone. For Merck, the play is straightforward: win in the gut, win on the skin, and stop trying to make the lungs happen.

Sometimes the most useful thing a clinical trial can do is tell you where not to look.

The Gene Editor That Might Actually Delete Hepatitis B

Precision BioSciences just showed the first clinical evidence that a gene editor can destroy cccDNA, the hidden viral reservoir that makes hepatitis B nearly impossible to cure. If it holds up, 250 million patients worldwide could finally have a path off lifelong medication.